Tuberculosis vaccine - Aeras/Crucell

Drug Profile

Tuberculosis vaccine - Aeras/Crucell

Alternative Names: AERAS-402/Crucell Ad35

Latest Information Update: 23 Nov 2015

Price : $50

At a glance

  • Originator Aeras Global TB Vaccine Foundation; Crucell
  • Developer Aeras; Crucell; National Institutes of Health (USA)
  • Class Antituberculars; Recombinant fusion proteins; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 20 Aug 2015 No recent reports on development identified - Phase-I for Tuberculosis (Prevention) in India (IM)
  • 01 Apr 2014 Aeras completes a phase II trial in Tuberculosis (in infants, prevention) in Kenya, Mozambique and South Africa (NCT01198366)
  • 29 Aug 2013 Aeras receives 5-year grant from Department for International Development in the United Kingdom for vaccine development in tuberculosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top